MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
0.9245
+0.0251
+2.79%
After Hours: 0.9189 -0.0056 -0.61% 19:51 06/12 EDT
OPEN
0.8901
PREV CLOSE
0.8994
HIGH
0.9591
LOW
0.8838
VOLUME
5.25M
TURNOVER
--
52 WEEK HIGH
4.079
52 WEEK LOW
0.8227
MARKET CAP
248.00M
P/E (TTM)
-11.9909
1D
5D
1M
3M
1Y
5Y
1D
Akebia announces new Vafseo patent
TipRanks · 3d ago
Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo
Benzinga · 3d ago
Akebia says new Vafseo dosing patent is listed in FDA Orange Book
PUBT · 3d ago
Weekly Report: what happened at AKBA last week (0601-0605)?
Weekly Report · 5d ago
Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each
PUBT · 06/01 20:07
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 20:05
Weekly Report: what happened at AKBA last week (0525-0529)?
Weekly Report · 06/01 09:48
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
Seeking Alpha · 05/28 13:18
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.